This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2007 Sep;18(9):2426-8.

doi: 10.1681/ASN.2007070783. Epub 2007 Aug 15.

Fabry nephropathy and the case for adjunctive renal therapy

Christoph Wanner, Frank Breunig

PMID: 17699807
DOI: 10.1681/ASN.2007070783

Review

Fabry nephropathy and the case for adjunctive renal therapy

Christoph Wanner et al. J Am Soc Nephrol. 2007 Sep.

. 2007 Sep;18(9):2426-8.

doi: 10.1681/ASN.2007070783. Epub 2007 Aug 15.

Authors

Christoph Wanner, Frank Breunig

PMID: 17699807
DOI: 10.1681/ASN.2007070783

No abstract available

PubMed Disclaimer

Comment on

Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
Tahir H, Jackson LL, Warnock DG. Tahir H, et al. J Am Soc Nephrol. 2007 Sep;18(9):2609-17. doi: 10.1681/ASN.2006121400. Epub 2007 Jul 26. J Am Soc Nephrol. 2007. PMID: 17656478 Clinical Trial.

Similar articles

Enzyme replacement therapy and Fabry nephropathy.
Warnock DG, Daina E, Remuzzi G, West M. Warnock DG, et al. Clin J Am Soc Nephrol. 2010 Feb;5(2):371-8. doi: 10.2215/CJN.06900909. Epub 2009 Dec 10. Clin J Am Soc Nephrol. 2010. PMID: 20007680
Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
Tahir H, Jackson LL, Warnock DG. Tahir H, et al. J Am Soc Nephrol. 2007 Sep;18(9):2609-17. doi: 10.1681/ASN.2006121400. Epub 2007 Jul 26. J Am Soc Nephrol. 2007. PMID: 17656478 Clinical Trial.
Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.
Warnock DG, Thomas CP, Vujkovac B, Campbell RC, Charrow J, Laney DA, Jackson LL, Wilcox WR, Wanner C. Warnock DG, et al. J Med Genet. 2015 Dec;52(12):860-6. doi: 10.1136/jmedgenet-2015-103471. Epub 2015 Oct 21. J Med Genet. 2015. PMID: 26490103 Free PMC article.
Agalsidase alfa slows the decline in renal function in patients with Fabry disease.
Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M; International Fabry Outcome Survey Investigators. Feriozzi S, et al. Am J Nephrol. 2009;29(5):353-61. doi: 10.1159/000168482. Epub 2008 Oct 31. Am J Nephrol. 2009. PMID: 18974635 Review.
New therapeutic strategies with combined renin-angiotensin system inhibitors for pediatric nephropathy.
Zaffanello M, Franchini M, Fanos V. Zaffanello M, et al. Pharmacotherapy. 2008 Jan;28(1):125-30. doi: 10.1592/phco.28.1.125. Pharmacotherapy. 2008. PMID: 18154482 Review.

See all similar articles

Cited by

Fabry's disease: an example of cardiorenal syndrome type 5.
Sharma A, Sartori M, Zaragoza JJ, Villa G, Lu R, Faggiana E, Brocca A, Di Lullo L, Feriozzi S, Ronco C. Sharma A, et al. Heart Fail Rev. 2015 Nov;20(6):689-708. doi: 10.1007/s10741-015-9500-0. Heart Fail Rev. 2015. PMID: 26232292 Review.
Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative review.
Oder D, Müntze J, Nordbeck P. Oder D, et al. Cardiovasc Diagn Ther. 2021 Apr;11(2):683-695. doi: 10.21037/cdt-20-743. Cardiovasc Diagn Ther. 2021. PMID: 33968645 Free PMC article. Review.
Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review.
Palaiodimou L, Kokotis P, Zompola C, Papagiannopoulou G, Bakola E, Papadopoulou M, Zouvelou V, Petras D, Vlachopoulos C, Tsivgoulis G. Palaiodimou L, et al. Curr Neuropharmacol. 2023;21(3):440-456. doi: 10.2174/1570159X20666220601124117. Curr Neuropharmacol. 2023. PMID: 35652398 Free PMC article. Review.
Fabry disease.
Germain DP. Germain DP. Orphanet J Rare Dis. 2010 Nov 22;5:30. doi: 10.1186/1750-1172-5-30. Orphanet J Rare Dis. 2010. PMID: 21092187 Free PMC article. Review.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Wolters Kluwer
Medical
- MedlinePlus Health Information